title: Detection and treatment of atherosclerosis using nanoparticles.
abstract: Atherosclerosis is the key pathogenesis of cardiovascular disease, which is a silent killer and a leading cause of death in the United States. Atherosclerosis starts with the adhesion of inflammatory monocytes on the activated endothelial cells in response to inflammatory stimuli. These monocytes can further migrate into the intimal layer of the blood vessel where they differentiate into macrophages, which take up oxidized low-density lipoproteins and release inflammatory factors to amplify the local inflammatory response. After accumulation of cholesterol, the lipid-laden macrophages are transformed into foam cells, the hallmark of the early stage of atherosclerosis. Foam cells can die from apoptosis or necrosis, and the intracellular lipid is deposed in the artery wall forming lesions. The angiogenesis for nurturing cells is enhanced during lesion development. Proteases released from macrophages, foam cells, and other cells degrade the fibrous cap of the lesion, resulting in rupture of the lesion and subsequent thrombus formation. Thrombi can block blood circulation, which represents a major cause of acute heart events and stroke. There are generally no symptoms in the early stages of atherosclerosis. Current detection techniques cannot easily, safely, and effectively detect the lesions in the early stages, nor can they characterize the lesion features such as the vulnerability. While the available therapeutic modalities cannot target specific molecules, cells, and processes in the lesions, nanoparticles appear to have a promising potential in improving atherosclerosis detection and treatment via targeting the intimal macrophages, foam cells, endothelial cells, angiogenesis, proteolysis, apoptosis, and thrombosis. Indeed, many nanoparticles have been developed in improving blood lipid profile and decreasing inflammatory response for enhancing therapeutic efficacy of drugs and decreasing their side effects. WIREs Nanomed Nanobiotechnol 2017, 9:e1412. doi: 10.1002/wnan.1412 For further resources related to this article, please visit the WIREs website.
authors.affiliation: Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.
authors.forename: Jia
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.
authors.forename: Yujiao
authors.initials: Y
authors.lastname: Zu
authors.affiliation: Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.
authors.forename: Chathurika S
authors.initials: CS
authors.lastname: Dhanasekara
authors.affiliation: Laboratory Animal Center, Peking University, Beijing, PR China.
authors.forename: Jun
authors.initials: J
authors.lastname: Li
authors.affiliation: Nutritional Immunology Laboratory, Jean Mayer Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA.
authors.forename: Dayong
authors.initials: D
authors.lastname: Wu
authors.affiliation: Department of Electrical and Computer Engineering and Nano Tech Center, Texas Tech University, Lubbock, TX, USA.
authors.forename: Zhaoyang
authors.initials: Z
authors.lastname: Fan
authors.affiliation: Department of Nutritional Sciences, Texas Tech University, Lubbock, TX, USA.
authors.forename: Shu
authors.initials: S
authors.lastname: Wang
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000175:diagnosis / Q000628:therapy; D004195:Disease Models, Animal; D042783:Endothelial Cells; D006801:Humans; D051379:Mice; D009000:Monocytes; D053758:Nanoparticles; D051381:Rats; D000068936:Theranostic Nanomedicine